Publication: Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
No Thumbnail Available
Identifiers
Date
2020-12-24
Authors
Bass, Ann D
Arroyo, Rafael
Boster, Aaron L
Boyko, Alexey N
Eichau, Sara
Ionete, Carolina
Limmroth, Volker
Navas, Carlos
Pelletier, Daniel
Pozzilli, Carlo
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405), with sustained efficacy in 2 consecutive extensions (NCT00930553, NCT02255656 [TOPAZ]). Post hoc analysis of 8-year alemtuzumab efficacy and safety in pooled CARE-MS patients (N=811) stratified by baseline age (≥18 to ≤25, >25 to ≤35, >35 to ≤45, >45 to ≤55 years). Compared with SC IFNB-1a over 2 years across age cohorts, alemtuzumab lowered annualized relapse rates (ARR; 0.22-0.24 vs. 0.38-0.51), improved or stabilized disability (freedom from 6-month confirmed disability worsening [CDW]: 85%-92% vs. 62%-88%; achievement of 6-month confirmed disability improvement [CDI]: 20%-31% vs. 13%-25%), increased proportions free of MRI disease activity (70%-86% vs. 42%-63% per year), and slowed brain volume loss (BVL; -0.45% to -0.87% vs. -0.50% to -1.39%). Through Year 2, the treatment effect with alemtuzumab did not significantly differ among age groups for ARR (p-interaction=0.6325), 6-month CDW-free (p-interaction=0.4959), 6-month CDI (p-interaction=0.9268), MRI disease activity-free (p-interaction=0.6512), and BVL (p-interaction=0.4970). Alemtuzumab remained effective on outcomes through Year 8 across age groups. Age-related increases in malignancies (≤45 years: 0.9%-2.2% vs. >45 years: 8.1%) and deaths (0%-1.7% vs. 7.0%) were observed. Serious infections also increased from the youngest (5.1%) to oldest (12.8%) age cohorts. Alemtuzumab had greater efficacy than SC IFNB-1a over 2 years across comparable age groups, with no significant differences between alemtuzumab-treated age groups. Efficacy on relapse, disability, and MRI outcomes continued through Year 8 across age groups. Age-related increases in serious infections, malignancies, and deaths were observed.
Description
MeSH Terms
Alemtuzumab
Antibodies, Monoclonal, Humanized
Child
Humans
Interferon beta-1a
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Treatment Outcome
Antibodies, Monoclonal, Humanized
Child
Humans
Interferon beta-1a
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Treatment Outcome
DeCS Terms
CIE Terms
Keywords
Age, Alemtuzumab, Efficacy, Long-term, Safety